Patents by Inventor Vibha Oza

Vibha Oza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325903
    Abstract: Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 10, 2022
    Assignee: Bantam Pharmaceutical, LLC
    Inventors: M. Arshad Siddiqui, Stephane Ciblat, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Nicolas Bruneau-Latour, Gerald W. Shipps, Alan B. Cooper, Vibha Oza, Matthew J. Kostura, Michael Luther, Jedd Levine
  • Patent number: 11192887
    Abstract: Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: December 7, 2021
    Assignee: Bantam Pharmaceutical, LLC
    Inventors: M. Arshad Siddiqui, Stephane Ciblat, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Nicolas Bruneau-Latour, Gerald W. Shipps, Alan B. Cooper, Vibha Oza, Matthew J. Kostura, Michael Luther, Jedd Levine
  • Publication number: 20200069656
    Abstract: Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “a”, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 5, 2020
    Inventors: Arshad M. Siddiqui, Stephane Ciblat, Lea Constantineau-Forget, Chantal Grand-Maitre, Xiangyu Guo, Jr., Sanjay Srivastava, Gerald W. Shipps, Alan B. Cooper, Vibha Oza, Matthew W. Kostura, Michael Luther, Jedd Levine
  • Publication number: 20190345152
    Abstract: Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
    Type: Application
    Filed: November 29, 2017
    Publication date: November 14, 2019
    Inventors: Arshad M. Siddiqui, Stephane Ciblat, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Nicolas Bruneau-Latour, Gerald W. Shipps, Alan B. Cooper, Vibha Oza, Matthew W. Kostura, Michael Luther, Jedd Levine
  • Publication number: 20100317593
    Abstract: Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers.
    Type: Application
    Filed: June 8, 2010
    Publication date: December 16, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Edward Hennessy, Alexander Hird, Vibha Oza, Jamal Carlos Saeh, Li Sha
  • Publication number: 20100197749
    Abstract: The invention relates to chemical compounds of formula (I) and (II): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: January 15, 2007
    Publication date: August 5, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Scott Cowen, Tracey Deegan, Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • Publication number: 20100029643
    Abstract: The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: November 8, 2007
    Publication date: February 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Paul Lyne, Vibha Oza, Jamal Carlos Saeh, Qibin Su, Bin Yang
  • Publication number: 20090233928
    Abstract: Compounds of the formula (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: March 7, 2006
    Publication date: September 17, 2009
    Inventors: David Andrews, Maurice Raymond Finlay, Clive Green, Clifford Jones, Vibha Oza
  • Publication number: 20090111860
    Abstract: The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins.
    Type: Application
    Filed: April 20, 2007
    Publication date: April 30, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • Publication number: 20090105324
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: April 20, 2007
    Publication date: April 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • Publication number: 20090054396
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: September 8, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
  • Patent number: 7423061
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: September 9, 2008
    Assignee: AstraZeneca AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Stephanie Springer, Mei Su, Dingwei Yu
  • Publication number: 20070149560
    Abstract: This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: March 10, 2004
    Publication date: June 28, 2007
    Applicant: AstraZeneca AB
    Inventors: Susan Ashwell, Jayachandran Ezhuthachan, Paul Lyne, Nicholas Newcombe, Martin Pass, Vibha Oza, Mei Su, Dorin Toader, Dingwei Yu, Yan Yu
  • Publication number: 20060281666
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: August 12, 2004
    Publication date: December 14, 2006
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Stephanie Springer, Mei Su, Dingwei Yu